Latigo Biotherapeutics LTGO
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 89th percentile, 5-year average -10.0x
Near the top of its 5-year range · 96th percentile, 5-year average -3.7x
#3263 of 5329 stocks by PB (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.21 | – | -3.69 | 96% (pricier than usual) | #3263 of 5329 (1 = cheapest) |
| PE | -8.10 | -6.41 | -10.01 | 89% (pricier than usual) | – |
| PS | – | – | 0.00 | – | – |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on LTGO.
Sign in to join the discussion.